Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2016 | EURO-SKI trial: cessation of TKI treatment in CML patients with deep molecular response

Press brief by Francois-Xavier Mahon, MD, PhD of University Hospital of Bordeaux, Bordeaux, France, on results of the EURO-SKI trial on cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia (CML) patients with deep molecular response held at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.